Achieve Life Sciences, Inc.
ACHV
$2.42
-$0.13-5.10%
| Weiss Ratings | ACHV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ACHV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ACHV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.04 | |||
| Price History | ACHV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -15.38% | |||
| 30-Day Total Return | -24.84% | |||
| 60-Day Total Return | -31.83% | |||
| 90-Day Total Return | -43.79% | |||
| Year to Date Total Return | -34.42% | |||
| 1-Year Total Return | -47.28% | |||
| 2-Year Total Return | -66.39% | |||
| 3-Year Total Return | -68.57% | |||
| 5-Year Total Return | -61.71% | |||
| 52-Week High % Change | -54.38% | |||
| 52-Week Low % Change | 4.51% | |||
| Price | ACHV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $5.59 | |||
| 52-Week Low Price | $2.44 | |||
| 52-Week Low Price (Date) | Apr 02, 2025 | |||
| 52-Week High Price (Date) | May 29, 2024 | |||
| Valuation | ACHV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 88.45M | |||
| Enterprise Value | 64.04M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.23 | |||
| Earnings Per Share Growth | -19.70% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 4.23 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $2.42 | |||
| Enterprise Value/EBITDA (TTM) | -1.65 | |||
| Enterprise Value/EBIT | -1.64 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ACHV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 34.51M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ACHV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 604 210 2217 | |||
| Address | 1040 West Georgia Street Vancouver, BC V6E 4H1 | |||
| Website | www.achievelifesciences.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | ACHV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ACHV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -84.19% | |||
| Return on Equity | -- | |||
| Income Statement | ACHV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -38.84M | |||
| EBIT (TTM) | -39.07M | |||
| Net Income (TTM) | -39.83M | |||
| Net Income Avl. to Common (TTM) | -39.83M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -125.71% | |||
| EPS Diluted (TTM) | -1.23 | |||
| EPS Diluted Growth (Q YOY) | -38.42% | |||
| Balance Sheet | ACHV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 34.36M | |||
| Cash Per Share (Q) | $1.00 | |||
| Total Current Assets (Q) | 36.47M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 20.90M | |||
| Current Ratio (Q) | 5.457 | |||
| Book Value Per Share (Q) | $0.60 | |||
| Total Assets (Q) | 38.63M | |||
| Total Current Liabilities (Q) | 6.68M | |||
| Total Debt (Q) | 9.96M | |||
| Total Liabilities (Q) | 17.73M | |||
| Total Common Equity (Q) | 20.90M | |||
| Cash Flow | ACHV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -21.58M | |||
| Cash from Financing (TTM) | 48.53M | |||
| Net Change in Cash (TTM) | -2.82M | |||
| Levered Free Cash Flow (TTM) | -18.34M | |||
| Cash from Operations (TTM) | -29.77M | |||
